155 BOVET RD., SUITE 303, SAN MATEO, CA
Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer
Investor Presentation
Announce Global License Agreement for Innovative Forms of Resmetirom API for Fixed Dose Combination Program
Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
News, Letter Re Change in Certifying Accountant
News, Legal Opinion, Material Contracts
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence